Clinical study of hepatectomy combined with Jianpi Huayu therapy for hepatocellular carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 14, 2014, Pages 5951-5957

  Zhong, Chong ^a   Li, Hui Dong ^a   Liu, Dong Yang ^a   Xu, Fa Bin ^a   Wu, Jian ^a   Lin, Xue Mei ^a   Guo, Rong Ping ^b  

^a Department of Hepatobilliary Surgery The First Affiliated Hospital to Traditional Chinese Medicine in Guangzhou   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Hepatectomy; Hepatocellular carcinoma; Jianpi Huayu therapy; Outcome

Indexed keywords

ALANINE AMINOTRANSFERASE; HERBACEOUS AGENT;

CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CHINA; CHINESE MEDICINE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIVER; LIVER NEOPLASMS; LIVER RESECTION; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TUMOR RECURRENCE;

ALANINE TRANSAMINASE; CARCINOMA, HEPATOCELLULAR; CHINA; DISEASE-FREE SURVIVAL; DRUGS, CHINESE HERBAL; FEMALE; HEPATECTOMY; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SURVIVAL RATE;

EID: 84905983988     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.14.5951     Document Type: Article

References (36)

1. Abdelgawad IA, Mossallam GI, Radwan NH, et al (2013). Can glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients? Asian Pac J Cancer Prev, 14, 7345-9.
2. Ahmad Z, Arshad H, Fatima S, et al (2013). Gastrointestinal, liver and biliary tract pathology: a histopathological and epidemiological perspective from Pakistan with a review of the literature. Asian Pac J Cancer Prev, 14, 6997-7005.
3. Berk V, Kaplan MA, Tonyali O, et al (2013). Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology. Asian Pac J Cancer Prev, 14, 7367-9.
4. Banjerdpongchai R, Wudtiwai B, Sringarm K (2013). Cytotoxic and apoptotic-inducing effects of purple rice extracts and chemotherapeutic drugs on human cancer cell lines. Asian Pac J Cancer Prev, 14, 6541-8.
5. Chittmittrapap S, Chieochansin T, Chaiteerakij, et al (2013). Prevalence of aflatoxin induced p53 mutation at codon 249 (R249s) in hepatocellular carcinoma patients with and without hepatitis B surface antigen (HBsAg). Asian Pac J Cancer Prev, 14, 7675-9.
6. Chen HL, Zhou DH (2003). The experience to treat liver cancer. J Traditional Chinese Med, 44, 894-895.
7. Caldwell S, Park SH (2009). The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol, 44, 96-101.
8. Chen XL, Wang BQ (2007). Introduction to pixu and the correlation of liver cancer. Trad Chin Med Jilin, 27, 5-7.
9. Cheung F, Wang X, Wang N, et al (2013). Chinese medicines as an adjuvant therapy for unresectable hepatocellular carcinoma during transarterial chemoembolization: a Meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med, 2013, 487919.
10. Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55.
11. Guo RP, Zhong C, Shi M, et al (2006). Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol, 132, 547-55.
12. Gupta SP, Mittal A, Sathian B, et al (2013). Elevated serum insulin is an independent risk factor for hepatocellular carcinoma: a case control study from Nepal. Asian Pac J Cancer Prev, 14, 7331-3.
13. Gao FY, Li YF, Zhang AQ (2011). Research progress of traditional Chinese medicine in the treatment of primary liver cancer. China Cancer, 20, 764-767.
14. Hao YX, Wang JP, Zhao LF (2013). Associations between three common MicroRNA polymorphisms and hepatocellular carcinoma risk in Chinese. Asian Pac J Cancer Prev, 14, 6601-4
15. Hu Y, Chen RS (2008). Treatment of liver cancer experience isintroduced. J New Chinese Med, 40, 12.
16. Liu XN, Li N (2012). Primary liver cancer clinical medication meta-analysis of traditional Chinese medicine. China J Chin Mater Med, 37, 1327-31.
17. Li GH, Chen MS, Li JQ, et al (2002). The effect of the resection of liver cancer and experience. Chinese J Hepatobiliary Surgery, 8, 190-1.
18. Ministry of Health of the People's Republic of China (2011). Primary liver cancer diagnosis and treatment standards (2011 edition), J Clin Oncol, 929-46.
19. Norsa'adah B, Nurhazalini-Zayani CG (2013). Epidemiology and survival of hepatocellular carcinoma in north-east Peninsular Malaysia. Asian Pac J Cancer Prev, 14, 6955-9
20. Shi M, Guo RP, Lin XJ, et al (2007). Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg, 245, 36-43.
21. Sobin LH, Gospodarowicz MK, Wittekind C (2019). International Union Against Cancer (UICC). TNM classification of malignant tumours (7thed)[S]. New York:Wiley-Liss, 80-85.
22. Su XK, Ye XW, Lin MQ, et al (2006). Method of 'jian pi hua yu '82 cases of postoperative recurrence of liver cancer clinical research. J Traditional Chinese Med, 47, 673-5.
23. Tang ZY (2011). Combine traditional Chinese and western medicine treatment of liver cancer. Combine traditional Chinese and western medicine liver disease 21, 129-30.
24. The state food and drug administration. Chinese medicine new medicine clinical research guiding principle (2002). Beijing: China medical science and technology press, kunming, China. 210-2.
25. Tian YZ, Li HY, Du HT (2012). Combine traditional chinese and western medicine treatment curative effect of liver cancer research. J Chinese Med, 27, 1246-7.
26. Wu MC, Chen H, Shen F (2001). Surgical treatment of primary liver cancer, with 5524 cases report. Chin J Surg, 39, 25-8.
27. Yang HL, (2013). The clinical value of w.k.che treated from the spleen liver cancer. J Traditional Chinese Med, 54, 623-4.
28. Yu RX (2001). Thinking of the TCM therapy for cancer. tumour, 21, 419-20
29. Ye SL, Qin SK, Wu MC, et al (2009). Experts consensus on diagnosis and treatment for primary hepatocellular carcinoma4.29 (4):295-304.
30. Zhu WJ, Huang CY, Li C, et al (2013). Risk factors for early recurrence of HBV-related hepatocellular carcinoma meeting milan criteria after curative resection. Asian Pac J Cancer Prev, 14, 7101-6.
31. Zekri Ael-R, Nassar AA, El-Din El-Rouby MN, et al (2013). Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation. Asian Pac J Cancer Prev, 14, 6721-6.
32. Zhang J, Wang R, Ma YY, et al (2013). Association between single nucleotide polymorphisms in miRNA196a-2 and miRNA146a and susceptibility to hepatocellular carcinoma in a Chinese population. Asian Pac J Cancer Prev, 14, 6427-31.
33. Zhong C, Guo RP, Li JQ, et al (2009). A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol, 135, 1437-45.
34. Zhang XW, Yan XJ, Zhou ZR, et al (2010). Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science, 328, 240-3.
35. Zhen XT, Lin LZ (2009). Experience in treatment of primary liver cancer is introduced. J New Chin Med, 41, 11-2.
36. Zhou XD, Tang ZY, Yang BH, et al (2001). Experience in 1000 cases of small liver cancer resection. Chin J Pract Surg, 21, 41-4.